I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ivan Marques Borrello, M.D.
Associate Professor of Oncology
Languages: English, Italian, Portuguese, Spanish
Expertise: Bone Marrow Transplant, Clinical Trials, Hematologic Malignancies, Immunotherapy, Medical Oncology, Multiple Myeloma
Research Interests: Adoptive T cell therapy using marrow infiltrating lymphocytes; Myeloma vaccines; Targeting MDSCs with PDE5 inhibition
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
APPOINTMENT PHONE: 410-955-8964
401 N. Broadway Baltimore, MD 21231
Phone: 410-955-4967 | Fax: 443-287-4653
Dr. Borrello is an associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics Core for the Johns Hopkins Kimmel Cancer Center. He is a member of the Hematologic Malignancies and Bone Marrow Translational Program.
Dr. Borrello's clinical research interest is in developing immune based therapies for the treatment of multiple myeloma. His laboratory interests have focused on the development of a novel approach of adoptive T cell therapy utilizing marrow infiltrating lymphocytes (MILs) as a more tumor specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins, and he is currently exploring this approach in other diseases including non-hematologic malignancies. Dr. Borrello is also examining strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines.
Dr. Borrello received his medical degree from the Medical College of Virginia, did his residency at the University of Chicaco and fellowship at Johns Hopkins.
- Associate Professor of Oncology
Departments / Divisions
- Oncology - Immunology and Hematopoiesis
Centers & Institutes
- Sidney Kimmel Comprehensive Cancer Center
- SKCCC Cell Therapy Core
- MD, Medical College of Virginia School of Medicine (1992)
- University of Chicago Pritzker School of Medicine - REGISTRAR / Internal Medicine (1995)
- Johns Hopkins University School of Medicine / Oncology (1998)
Research & Publications
Clinical Trial Keywordsmultiple myeloma
Learn more about clinical trials at the Johns Hopkins Kimmel Cancer Center.
Selected PublicationsView all on Pubmed
Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K., Borrello I. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Canc Res 2005; 65:2026-34.
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006 Nov 27; 203(12):2691-702. Epub 2006 Nov 13. PMCID: PMC2118163.
Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhy C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21(1):30-8. PMCID:PMC4329916
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenston MM, Cattry D, Freeman GJ, Rodiq SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P..PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.The New England journal of medicine. 2015; 372(4):311-9. PMCID: PMC4348009
Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014. PMID: 25995224